[US-헬스케어] 09/24 Wall St. Recap

As a senior equity analyst, the recent strategic developments for Eli Lilly and Co (LLY) highlight robust growth catalysts. The company recently closed a $2.8 Billion Deal and entered into a collaborative research agreement for nucleic acid therapeutics targeting neurological disorders, demonstrating its commitment to expanding its pipeline beyond metabolic diseases. Furthermore, major financial institutions like Berenberg have upgraded LLY, capitalizing on its unmatched market strength in obesity treatments. These strategic moves reinforce the company’s long-term future cash flows and solidify its leadership in high-growth therapeutic areas, driving positive investor sentiment.

As a senior equity analyst, the recent price action of Novo Nordisk A/S (NVO) following its Capital Markets Day reflects investor anxiety over post-Wegovy growth catalysts. Despite management unveiling an ambitious (10-year strategic blueprint), the market reacted with a sharp pullback—dropping over 7% initially and continuing downward—due to a lack of immediate, tangible milestones beyond current blockbusters. While the company’s long-term fundamentals in the (obesity and diabetes markets) remain robust, the current valuation already prices in immense optimism, leaving little room for near-term execution risks or (strategic disappointment). Therefore, we maintain a cautious near-term outlook as the stock digests these elevated expectations.

As a senior equity analyst, I evaluate Amgen’s (AMGN) recent developments as a net positive for its long-term growth trajectory. The company is actively strengthening its oncology portfolio, notably through the potential label expansion of (Small Cell Lung Cancer Maintenance Therapy), which opens up a larger addressable market. Furthermore, operational enhancements such as reducing the initial monitoring time for (IMDELLTRA) to 6-8 hours significantly improve (Convenience and Healthcare Efficiency), thereby accelerating clinical adoption and patient retention. Despite short-term market noise, these clinical and operational catalysts reinforce Amgen’s competitive moat in the specialized therapeutics space.

As a senior equity analyst, I evaluate the recent news surrounding UnitedHealth Group (UNH). The company’s decision to divest its (OptumHealth Florida clinic stake) to private equity firm TPG has triggered a (5% stock decline), reflecting near-term market anxiety over asset restructuring and portfolio optimization. While this move is part of management’s broader strategy to accelerate a (turnaround) and streamline operations following recent cost pressures, the immediate reaction highlights investor sensitivity to asset sales in key regional markets. Despite a strong medium-term rally over the past six months, the immediate execution risks and headwinds weigh on current sentiment.

As a senior equity analyst, I evaluate Pfizer Inc. ((PFE)) based on its strategic updates and market valuation. A key development is the company’s upward revision of its (2026 Revenue Guidance) to ($62 Billion), signaling robust long-term growth prospects and recovering operational momentum despite recent stock appreciation. While investors debate whether the recent (24% Stock Rally) makes the shares overvalued, this aggressive guidance beat underpins fundamental value creation, justifying a favorable outlook.